Perceptive Advisors’s Orchestra BioMed OBIO Stock Holding History

Perceptive Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.4M	Sell	5,037,906 -89,350	-2%	-$380K	0.42%	51
2025 Q4	$21.3M	Sell	5,127,256 -165,300	-3%	-$667K	0.38%	60
2025 Q3	$13.1M	Buy	5,292,556 +700,000	+15%	+$1.93M	0.38%	50
2025 Q2	$12.3M	Hold	4,592,556	–	–	0.46%	49
2025 Q1	$19.7M	Hold	4,592,556	–	–	0.69%	36
2024 Q4	$18.4M	Hold	4,592,556	–	–	0.51%	43
2024 Q3	$23.6M	Buy	4,592,556 +2,046,675	+80%	+$13.4M	0.5%	51
2024 Q2	$20.7M	Hold	2,545,881	–	–	0.5%	55
2024 Q1	$13.4M	Buy	2,545,881 +113,792	+5%	+$771K	0.23%	70
2023 Q4	$22.2M	Hold	2,432,089	–	–	0.5%	49
2023 Q3	$21.2M	Buy	2,432,089 +379,221	+18%	+$2.55M	0.71%	41
2023 Q2	$14.4M	Sell	2,052,868 -225,358	-10%	-$3.42M	0.42%	59
2023 Q1	$44.6M	Buy	+2,278,226	New	+$26.4M	1.32%	20
2022 Q2	–	Sell	-450,000	Closed	-$4.46M	–	119
2022 Q1	$4.46M	Hold	450,000	–	–	0.09%	109
2021 Q4	$4.54M	Hold	450,000	–	–	0.07%	123
2021 Q3	$4.45M	Hold	450,000	–	–	0.06%	123
2021 Q2	$4.59M	Hold	450,000	–	–	0.06%	127
2021 Q1	$5.04M	Hold	450,000	–	–	0.06%	114
2020 Q4	$5.76M	Hold	450,000	–	–	0.06%	117
2020 Q3	$4.95M	Buy	+450,000	New	+$5.05M	0.07%	102

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

DMKJ

David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Perceptive Advisors's OBIO Position: Q1 2026 in Review

Perceptive Advisors reduced its Orchestra BioMed (OBIO) stake by 1.7% in Q1 2026, selling an estimated $380K and leaving 5,037,906 shares worth $21.4M. The position accounts for 0.42% of the portfolio, ranked #51.

Perceptive Advisors first reported a position in OBIO in Q3 2020 and has held it in 20 quarters since. The position peaked at $44.6M in Q1 2023. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

Perceptive Advisors held 5,037,906 shares of Orchestra BioMed worth $21.4M as of Q1 2026.
Perceptive Advisors sold 89,350 Orchestra BioMed shares in Q1 2026, an estimated $380K.
Orchestra BioMed made up 0.42% of Perceptive Advisors's portfolio in Q1 2026, its #51 holding.
Perceptive Advisors first reported a position in Orchestra BioMed in Q3 2020 and has held it in 20 quarters since.
Perceptive Advisors's Orchestra BioMed position peaked at $44.6M in Q1 2023.
65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.